BRAIN CANCER

Latest News

NCCN Adds Naxitamab to Practice Guidelines for High-Risk Neuroblastoma
NCCN Adds Naxitamab to Practice Guidelines for High-Risk Neuroblastoma

May 9th 2025

The anti-GD2 therapy naxitamab has been included in the NCCN Clinical Practice Guidelines in Oncology for the treatment of patients with neuroblastoma.

FDA Issues CRL to TLX101-CDx, a Novel PET Imaging Agent for Glioma
FDA Issues CRL to TLX101-CDx, a Novel PET Imaging Agent for Glioma

May 1st 2025

Well-Tolerated TLX101 Shows Efficacy in Recurrent Glioma
Well-Tolerated TLX101 Shows Efficacy in Recurrent Glioma

April 17th 2025

FDA Approves IDE Application for Alpha DaRT in Recurrent Glioblastoma
FDA Approves IDE Application for Alpha DaRT in Recurrent Glioblastoma

April 3rd 2025

More News